T1	p 54 130	previously untreated advanced breast cancer -- a cancer and leukemia group B
T2	p 536 567	the Cancer and Leukemia Group B
T3	p 576 620	) master metastatic breast cancer protocol .
T4	p 627 704	8642 randomizes previously untreated metastatic breast cancer patients either
T5	p 1271 1333	to have histologically documented measurable breast cancer and
T6	p 1358 1361	0-1
T7	p 1388 1435	had prior chemotherapy for metastatic disease .
T8	p 1800 1801	3
T9	p 1837 1838	3
T10	p 2163 2171	patients
T11	p 2176 2192	thrombocytopenia
T12	p 2284 2329	previously untreated breast cancer patients .
T13	p 2472 2491	patients adequately
T14	p 2524 2538	hematotoxicity
T15	p 2541 2562	with amonafide ranged
T16	i 6 17	Amonafide :
T17	i 154 163	Amonafide
T18	i 173 178	imide
T19	i 193 208	naphthalic acid
T20	i 496 507	. Amonafide
T21	i 568 569	(
T22	i 776 842	followed by standard cyclophosphamide-doxorubicin-5-fluorouracil ,
T23	i 1065 1104	agents precedes standard chemotherapy .
T24	i 1133 1142	amonafide
T25	i 1442 1463	adjuvant chemotherapy
T26	i 1522 1531	Amonafide
T27	i 2252 2261	amonafide
T28	o 371 389	plasma and urine .
T29	o 464 474	metabolite
T30	o 477 497	N-acetyl-amonafide .
T31	o 988 1030	survival , toxicity , and overall response
T32	o 1336 1354	performance status
T33	o 1520 1521	.
T34	o 1724 1742	thereof . Toxicity
T35	o 1800 1817	3 or 4 leukopenia
T36	o 1837 1841	3 or
T37	o 1844 1860	thrombocytopenia
T38	o 1875 1885	leukopenia
T39	o 1902 1938	thrombocytopenia . The response rate
T40	o 1973 1983	response .
T41	o 2014 2038	hematological toxicity ,
T42	o 2083 2103	leukopenia grade 3/4
T43	o 2176 2202	thrombocytopenia grade 3/4
T44	o 2351 2370	dose-response curve
T45	o 2398 2468	correlation between myelosuppression and response . Rates of responses